new version V2017

venous thrombosis
Description Results

     

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

antithrombotics

apixaban
CAP ongoing apixaban - NCT02581176
CARAVAGGIO ongoing apixabandalteparin - NCT03045406
aspirin
WARFASA, 2012aspirindiscontinuationSuggestingNCT00222677
ASPIRE, 2012aspirindiscontinuationSuggestingACTRN12605000004662
Bemiparin
Kakkar, 2003Bemiparinwarfarin Risk of bias Negative
dalteparin
Bratt et al , 1985Dalteparinunfractionated heparinNegative
Holm et al , 1986Dalteparinunfractionated heparinNegative
Bratt et al, 1990Dalteparinunfractionated heparinNegative
Holmström, 1992once daily dalteparintwice daily dalteparinNegative
Lindmarker et al , 1993Dalteparinunfractionated heparinNegative
Partsch, 1996once daily dalteparintwice daily dalteparinNegative
Das, 1996Dalteparinwarfarin Risk of bias Negative
CLOT (Lee), 2003extended dalteparinstandard treatmentSuggesting
Lee, 2003Dalteparinwarfarin Risk of bias Suggesting
edoxaban
Hokusai-VTE Cancer, 2017edoxabandalteparinpatients with cancerNegative NCT02073682
enoxaparin
Simonneau et al , 1993Enoxaparinunfractionated heparinNegative
Pini, 1994Enoxaparinwarfarin Risk of bias Negative
Gonzalez-Fajardo, 1999Enoxaparinwarfarin Risk of bias Suggesting
Veiga, 2000Enoxaparinacenocoumarol Risk of bias Negative
Merli, 2001once daily enoxaparintwice daily enoxaparinNegative
Merli (once daily vs UFH), 2001once daily enoxaparinUFH Low risk of bias Negative
Meyer, 2002extended enoxaparinstandard treatmentNegative
Meyer, 2002Enoxaparinwarfarin Risk of bias Negative
Cesarone, 2003extended enoxaparinstandard treatmentNegative
Deitcher, 2003Enoxaparinwarfarin Risk of bias Negative
Deitcher, 2006extended enoxaparinstandard treatmentNegative
González-Fajardo, 2008Enoxaparincoumarin Risk of bias -
fondaparinux
MATISSE, 2004fondaparinuxenoxaparin Low risk of bias Negative
heparin
Krahenbuhl, 1979subcutaneous heparinintravenous heparin -
Bentley, 1980subcutaneous heparinintravenous heparinSuggesting
Andersson, 1982subcutaneous heparinintravenous heparin -
Hull, 1986subcutaneous heparinintravenous heparinNegative
Doyle, 1987subcutaneous heparinintravenous heparinNegative
Walker, 1987subcutaneous heparinintravenous heparinSuggesting
Pini, 1990subcutaneous heparinintravenous heparinNegative
Nielsen importé, 1994heparin+phenprocoumonphenylbutazone -
Ott importé, 1998heparin+warfarinplaceboNegative
Lopaciuksubcutaneous heparinintravenous heparinNegative
idraparinux
Van Gogh (subgroup), 2011idraparinuxstandard treatmentpatients with cancer Exploratory Negative
logiparin
Siegbahn, 1989once daily logiparintwice daily logiparinNegative
nadroparin
Collaborative European Multicentre, 1991Nadroparinunfractionated heparinNegative
Prandoni et al , 1992Nadroparinunfractionated heparinSuggesting
Lopaciuk et al , 1992Nadroparinunfractionated heparinNegative
Charbonnier, 1998once daily nadroparintwice daily nadroparinNegative
Lopaciuk, 1999Nadroparinacenocoumarol Risk of bias Negative
Lopez-Beret, 2001Nadroparinacenocoumarol Risk of bias Negative
Lopez Beret, 2001extended nadroparinstandard treatmentNegative
rivaroxaban
SELECT D, 2018rivaroxabandalteparinpatients with cancerSuggesting
CONKO-011 ongoing rivaroxaban - NCT02583191
CASTA-DIVA ongoing rivaroxaban - NCT02746185
tinzaparin
Hull et al , 1992Tinzaparinunfractionated heparinSuggesting
Hull, 2002Tinzaparinwarfarin Risk of bias Negative
Hull, 2006extended tinzaparinstandard treatmentNegative
Romera, 2009Tinzaparinacenocoumarol Risk of bias Suggesting
warfarin
Schulman, 19956 months1.5 monthsSuggesting
Levine, 1995warfarindiscontinuationSuggesting
DURAC (Schulman), 1997warfarindiscontinuationSuggesting
LAFIT (Kearon), 1999warfarindiscontinuationSuggesting
Pinede, 20013-6 months1.5-3 monthsNegative
Agnelli, 2001warfarindiscontinuationNegative
Agnelli, 2003warfarindiscontinuationNegative
PREVENT (Ridker), 2003warfarindiscontinuationSuggesting
ELAET (Kearon), 2004warfarindiscontinuationNegative
Wells (subgroup), 2005tinzaparindalteparinNegative
ximelagatran
THRIVE III, 2003ximelagatrandiscontinuation Low risk of bias Suggesting
THRIVE I, 2003ximelagatran (without LMWH)LMWH/VKA -
Schulman (subgroup), 2003ximelagatranplacebopatients with cancer -
Fiessinger , 2005ximelagatranLMWH/VKA -

caval filter

caval filter
PREPIC, 1998caval filterno filter Low risk of bias Suggesting

direct oral anticoagulant (DAO)

apixaban
Botticelli DVT, 2008apixaban (without LMWH)LMWH/VKA Exploratory - NCT00252005
AMPLIFY-EXT 2.5mg, 2012apixaban 2.5mgdiscontinuationSuggestingNCT00633893
AMPLIFY-EXT 5mg, 2012apixaban 5mgdiscontinuationSuggestingNCT00633893
AMPLIFY, 2013apixaban (without LMWH)LMWH/VKA Low risk of bias SuggestingNCT00643201
dabigatran
RE-COVER, 2009heparin/dabigatranheparin/VKA Low risk of bias SuggestingNCT00291330
RE-SONATE, 2011dabigatrandiscontinuationSuggestingNCT00558259
RE-COVER II, 2011heparin/dabigatranheparin/VKASuggestingNCT00680186
RE-MEDY, 2011dabigatranwarfarin Low risk of bias SuggestingNCT00329238
edoxaban
Edoxaban Hokusai VTE, 2013heparin/edoxabanheparin/VKA Low risk of bias SuggestingNCT00986154
fondaparinux
MATISSE PE, 2003fondaparinuxheparin Risk of bias Negative
idraparinux
VanGogh DVT, 2007idraparinux (without heparin)heparin/VKA Exploratory SuggestingNCT00067093
VanGogh PE, 2007idraparinux (without heparin)heparin/VKA Risk of bias Negative NCT00062803
rivaroxaban
Einstein-DVT Dose-Ranging Study, 2008rivaroxaban (without LMWH)LMWH/VKA -
EINSTEIN-extension, 2009rivaroxabandiscontinuation Low risk of bias Suggesting NCT00439725
Einstein-DVT Evaluation, 2010rivaroxaban (without LMWH)LMWH/VKA Low risk of bias SuggestingNCT00440193
Einstein-PE Evaluation, 2012rivaroxaban (without LMWH)LMWH/VKA Risk of bias - NCT00439777
rosuvastatin
VanGogh extension, 2007idraparinuxdiscontinuationSuggesting NCT00071279

fibrinolysis

heparin
Schweizer tPA, 1998tPA+heparinno fibrinolysisNegative
streptokinase
Kakkar (streptokinase), 1969streptokinaseno fibrinolysisNegative
Tsapogas, 1973streptokinaseno fibrinolysisNegative
Common, 1976streptokinaseno fibrinolysisNegative
Arneson, 1978streptokinaseno fibrinolysisNegative
Schulman, 1986streptokinaseno fibrinolysisNegative
Schweizer (systemic SK), 2000streptokinaseno fibrinolysis -
Elsharawy, 2002streptokinaseno fibrinolysisNegative
t-pa
Verhaeghe (high dose), 1989tPAno fibrinolysis -
Verhaeghe (low dose), 1989tPAno fibrinolysis -
Goldhaber (tPA alone), 1990tPAno fibrinolysisNegative
Turpie, 1990tPAno fibrinolysisNegative
Goldhaber (tPA+heparin), 1990tPAno fibrinolysis -
Schweizer (local tPA), 2000tPAno fibrinolysis -
urokinase
Kiil, 1981urokinaseno fibrinolysisNegative
Schweizer (urokinase), 1998urokinaseno fibrinolysisNegative
Schweizer (local urokinase), 2000urokinaseno fibrinolysis -
Schweizer (systemic urokinase), 2000urokinaseno fibrinolysis -



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons